Navigation Links
New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO® and a Common Antiretroviral Therapy
Date:7/18/2011

actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, Lilly and Kowa abilities to successfully commercialize and market LIVALO, competition from other pharmaceutical companies (including generic versions of other statin products), potential regulatory developments affecting the product, and other factors described in Lilly's most recent filings with the Securities and Exchange Commission. For additional information about the factors that affect the company's business, please see Lilly's latest Form 10-K, filed February 2009, and Form 10-Q filed October 2009. Lilly undertakes no duty to update forward-looking statements.

LIVALO is a registered trademark of the Kowa group of companies.

PS72893 LIV-MT-124


'/>"/>
SOURCE Kowa Pharmaceuticals America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
2. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
3. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
4. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
5. New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
6. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
7. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
8. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
9. Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
10. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
11. Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced the ... the compounding, packaging and distributing of its naltrexone tablets.  The ... United States . KRS Global is ... tablets in various strengths for individual patients in response to ...
(Date:1/23/2015)... GAINESVILLE, Fla. , Jan. 23, 2015  HyGreen, Inc., ... distribution agreement and partnership with RCA Medical, a subsidiary ... Africa . Each year, hundreds of ... health care-associated infections as organisms are transmitted from patient ...
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Addrenex Pharmaceuticals today expanded its pipeline of ... of an agreement to license a new drug ... debilitating sleep disorder, as well as other neurologic ... Addrenex the worldwide rights (excluding East Asia) to ...
... Circassia Ltd, a specialty,biopharmaceutical company focused on allergy, ... clinical development programme for its ragweed allergy,therapy. The ... based on Circassia,s ToleroMune(R) technology, which has previously,achieved ... allergies. Ragweed,is one of the leading causes of ...
Cached Medicine Technology:Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy 2Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy 3Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy 2
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... January 22, 2015 Joan Lunden, award-winning ... speaker at the upcoming 32nd Annual Miami Breast ... Physicians’ Education Resource®, LLC (PER®) , shares that “a ... gone undetected if she had not followed up her ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 As ... of overall health care gains momentum worldwide, Rev. Eric ... HealthCare Chaplaincy Network (HCCN), will be the keynote ... spiritual care in Israel’s public health system. , The conference, ...
(Date:1/22/2015)... 22, 2015 Step into a macabre ... Science Museum of Virginia. Wicked Plants, the Museum’s latest ... unearths 75 poisonous, carnivorous and diabolical plants inside of ... to uncover the biochemical, physical and neurological processes between ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... risk of unintentionally overdosing on over-the-counter (OTC) pain medication, ... Dr. Michael Wolf, from Northwestern University in Chicago, and ... potential misuse of pain medication containing the active ingredient ... online in the Journal of General Internal Medicine ...
... Patricia Dickson, M.D., principal investigator at The Los ... BioMed), is co-principal investigator of a project that was ... Institute for Regenerative Medicine (CIRM). The goal of ... therapy for the treatment of mucopolysaccharidosis I (MPS I), ...
... TUESDAY, May 29 (HealthDay News) -- If you want to ... say researchers who have found that centenarians are often extroverts ... The findings stem from the Longevity Genes Project, launched ... City. All the participants in the latest study were over ...
... of methotrexate (MTX) safety data found that injection ... superior to oral therapy in long-term treatment of ... in Arthritis Care & Research , a ... (ACR), suggest that with similar efficacy and tolerability ...
... A popular European fitness routine called Nordic walking improves the ... study. In Nordic walking, people walk with poles and ... skiing. This fast-growing form of exercise in Europe is safe ... quality of life and reduces their risk of hospitalization, but ...
... STANFORD, Calif. A specific antioxidant supplement may be ... to a pilot trial from the Stanford University School ... 31 children with the disorder. The antioxidant, called ... as well as reducing the children,s repetitive behaviors. The ...
Cached Medicine News:Health News:Misuse of over-the-counter pain medication is potential health threat 2Health News:LA BioMed's Dr. Patricia Dickson researching treatments for neurodegenerative disorders 2Health News:Optimism, Laughter May Bring Long Life 2Health News:Optimism, Laughter May Bring Long Life 3Health News:Injection of methotrexate not superior to oral therapy in juvenile arthritis treatment 2Health News:'Nordic Walking' a Winner for Heart Failure Patients, Study Says 2Health News:Antioxidant shows promise as treatment for certain features of autism, Stanford study finds 2Health News:Antioxidant shows promise as treatment for certain features of autism, Stanford study finds 3
Used for arthroscopic or open shoulder surgery. Powered positioning of back section inclines from 0 degrees to 90 degrees. Removable shoulder panels provide an eight-inch (203-mm) access area behind ...
... part in our daily lives. But degenerative ... cause severe handicaps. A decisive consideration in ... to produce a reconstructed joint function that ... possible.,The cementless RM Finger System has proven ...
... an important part in our daily lives. ... changes can cause severe handicaps. A decisive ... prostheses was to produce a reconstructed joint ... as nearly possible.,The cementless RM Finger System ...
... the use of sand bags under the drape during ... shaped for optimal foot contact and positioning the leg ... be used under the drape by attaching it to ... for use on top of the drape. It can ...
Medicine Products: